— Know what they know.
Not Investment Advice
Also trades as: SN.L (LSE) · $vol 44M · SNN (NYSE) · $vol 30M

SNNUF OTC

Smith & Nephew plc
1W: +7.0% 1M: +15.3% 3M: -6.7% YTD: -8.5% 1Y: +3.3% 3Y: +7.0% 5Y: -18.9%
$15.75
+0.65 (+4.30%)
 
Weekly Expected Move ±10.6%
$12 $13 $15 $17 $18
OTC · Healthcare · Medical - Devices · Alpha Radar Buy · Power 70 · $13.3B mcap · 823M float · 0.0002% daily turnover · Short 39% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$13.3B
52W Range13.1-18.5
Volume300
Avg Volume1,443
Beta0.68
Dividend$0.39
Analyst Ratings
7 Buy 9 Hold 1 Sell
Consensus Hold
Company Info
CEODeepak S. Nath
Employees17,349
SectorHealthcare
IndustryMedical - Devices
IPO Date2009-04-21
Building 5
Watford, HR WD18 8YE
GB
44 1923 477 100
About Smith & Nephew plc

Smith & Nephew plc is a global medical technology enterprise dedicated to the development, manufacturing, and worldwide commercialization of an extensive array of medical devices. Its product portfolio spans several key areas. In orthopedics, the company provides knee implants for replacement procedures, hip implants for joint reconstruction, and trauma and extremities products, including both internal and external fixation devices, crucial for stabilizing severe fractures and correcting deformities. For sports medicine, Smith & Nephew offers joint repair solutions tailored for surgeons. This includes specialized instruments, advanced technologies, and implants essential for minimally invasive joint surgeries, targeting soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, the firm supplies arthroscopic enabling technologies that enhance surgical visualization and intervention within joints. This suite encompasses fluid management equipment for surgical access, high-definition cameras, digital imaging capture systems, scopes, light sources, and monitors. It also features radiofrequency, electromechanical, and mechanical tissue resection devices, alongside hand instruments for precise tissue removal. The company also provides dedicated ear, nose, and throat (ENT) solutions. Its Advanced Wound Management division delivers comprehensive solutions for the treatment and prevention of acute and chronic wounds, covering conditions like leg, diabetic, and pressure ulcers, burns, and post-operative wounds. This segment includes advanced wound bioactives, comprising biologics and other bioactive technologies for debridement, dermal repair, and regeneration. Regenerative medicine products, such as skin, bone graft, and articular cartilage substitutes, are also offered. Furthermore, Smith & Nephew provides advanced wound devices, including traditional and single-use negative pressure wound therapy systems, and hydrosurgery technology. Primarily serving healthcare providers globally, Smith & Nephew plc was founded in 1856 and is headquartered in Watford, United Kingdom.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms